Literature DB >> 21282875

Transition from asymptomatic diastolic dysfunction to heart failure with preserved ejection fraction: roles of systolic function and ventricular distensibility.

Yoshihiro Aizawa1, Yasushi Sakata, Toshiaki Mano, Yasuharu Takeda, Tomohito Ohtani, Shunsuke Tamaki, Yosuke Omori, Yasumasa Tsukamoto, Atsushi Hirayama, Issei Komuro, Kazuhiro Yamamoto.   

Abstract

BACKGROUND: Systolic abnormality, as well as diastolic dysfunction, is observed in patients with heart failure with preserved ejection fraction (HFPEF). However, the role of these 2 conditions in the transition from asymptomatic diastolic dysfunction to symptomatic heart failure remains unclear. We recently demonstrated that diastolic wall strain (DWS) inversely correlates to the myocardial stiffness constant. METHODS AND
RESULTS: This study consisted of 127 subjects: 52 consecutive HFPEF patients (HFPEF group), 50 asymptomatic hypertensive patients with ejection fraction ≥50% whose age, gender and left ventricular (LV) mass index matched those of the HFPEF group (HT group) and 25 normal volunteers (Normal group). The tissue Doppler-derived peak systolic and early diastolic velocities of the mitral annulus were significantly decreased in groups HFPEF and HT than in group Normal, but were not significantly different between groups HFPEF and HT. DWS was significantly lower in group HFPEF than in group HT.
CONCLUSIONS: The transition from asymptomatic diastolic dysfunction stage to HFPEF stage is not attributed to progression of systolic abnormality, and exacerbation of LV distensibility rather than relaxation plays a crucial role in the development of HFPEF.

Entities:  

Mesh:

Year:  2011        PMID: 21282875     DOI: 10.1253/circj.cj-10-1037

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  7 in total

Review 1.  The emerging epidemic of heart failure with preserved ejection fraction.

Authors:  A Afşin Oktay; Jonathan D Rich; Sanjiv J Shah
Journal:  Curr Heart Fail Rep       Date:  2013-12

2.  Association between high-sensitivity troponin T, left ventricular hypertrophy, and myocardial performance index.

Authors:  Onur Kaypakli; Mustafa Gür; Mehmet Yavuz Gözükara; Hakan Uçar; Ali Kivrak; Taner Şeker; Durmuş Yildiray Şahin; Zafer Elbasan; Caner Türkoğlu; Murat Çayli
Journal:  Herz       Date:  2015-06-19       Impact factor: 1.443

3.  Left ventricular stiffness estimated by diastolic wall strain is associated with paroxysmal atrial fibrillation in structurally normal hearts.

Authors:  Shunsuke Uetake; Mitsunori Maruyama; Teppei Yamamoto; Katsuhito Kato; Yasushi Miyauchi; Yoshihiko Seino; Wataru Shimizu
Journal:  Clin Cardiol       Date:  2016-10-07       Impact factor: 2.882

4.  AV timing in pacemaker patients with first-degree AV block: which is preferable, intrinsic AV conduction or pacing?

Authors:  Yoshihiro Aizawa; Toshiko Nakai; Yukitoshi Ikeya; Rikitake Kogawa; Yuki Saito; Kazuto Toyama; Tetsuro Yumikura; Naoto Otsuka; Koichi Nagashima; Yasuo Okumura
Journal:  Heart Vessels       Date:  2022-02-08       Impact factor: 1.814

5.  N-terminal pro-B-type natriuretic peptide level inversely associates with metabolic syndrome in elderly persons.

Authors:  Ji-Hung Wang; Chung-Jen Lee; Jen-Che Hsieh; Yu-Chih Chen; Bang-Gee Hsu
Journal:  Diabetol Metab Syndr       Date:  2014-02-08       Impact factor: 3.320

6.  Patients with left ventricular ejection fraction greater than 58 % have fewer incidences of future acute decompensated heart failure admission and all-cause mortality.

Authors:  Toshihiko Goto; Kazuaki Wakami; Hidekatsu Fukuta; Hiroshi Fujita; Tomomitsu Tani; Nobuyuki Ohte
Journal:  Heart Vessels       Date:  2015-03-14       Impact factor: 2.037

7.  Comprehensive assessment of systemic arteriosclerosis in relation to the ocular resistive index in acute coronary syndrome patients.

Authors:  Yasunari Ebuchi; Taiji Nagaoka; Daisuke Fukamachi; Keisuke Kojima; Naotaka Akutsu; Nobuhiro Murata; Yuki Saito; Daisuke Kitano; Harumasa Yokota; Satoru Yamagami; Yasuo Okumura
Journal:  Sci Rep       Date:  2022-02-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.